Literature DB >> 9045996

Radioligand binding and immunoautoradiographic evidence for a lack of toxicity to dopaminergic nerve terminals in human cocaine overdose victims.

J K Staley1, J Z Talbot, B J Ciliax, G W Miller, A I Levey, M P Kung, H F Kung, D C Mash.   

Abstract

Radioligand binding to and immunolabeling of transport sites associated with monoamine-containing synaptic vesicles affords a novel approach for mapping the integrity of dopaminergic (DAergic) nerve terminals. The present study used [125I]iodovinyltetrabenazine ([125I]TBZ) and a fusion protein antibody directed at the large intraluminal loop of the neuronal vesicular monoamine transporter (hVMAT2-loop) as probes to assess the effects of chronic cocaine use on the integrity of DAergic nerve terminals in the striatum of cocaine fatalities. Visualization of [125I]TBZ binding in human brain revealed a distinct pattern of labeling throughout the rostral-caudal extent of the striatum. Saturation binding of [125I]TBZ in striatal membranes demonstrated a single high affinity site (Kd = 2.3 +/- 0.9 nM and Bmax = 55.5 +/- 8.1 pmol/g tissue) with a pharmacological profile (tetrabenazine > or = iodovinyltetrabenazine > ketanserin > or = reserpine > haloperidol > GBR 12909) consistent with the specific labeling of hVMAT2. Quantitative in vitro autoradiography demonstrated no significant alteration in the density of [125I]TBZ binding sites in the anterior and posterior sectors of the striatum in cocaine fatalities with and without preterminal excited delirium as compared to drug-free and age-matched control subjects. Similarly, the levels of hVMAT2-loop immunoreactivity were not significantly different across control and cocaine fatality groups. The results demonstrate the lack of an alteration in [125I]TBZ binding sites and hVMAT2 protein in the striatum from a young cohort of cocaine fatalities. Since striatal VMAT2 is primarily associated with DAergic nerve terminals, these results suggest that chronic cocaine use failed to affect the integrity of striatal DAergic nerve terminals.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9045996     DOI: 10.1016/s0006-8993(96)01196-1

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  11 in total

1.  Decreased vesicular monoamine transporter type 2 availability in the striatum following chronic cocaine self-administration in nonhuman primates.

Authors:  Rajesh Narendran; Hank P Jedema; Brian J Lopresti; Neale Scott Mason; Michael L Himes; Charles W Bradberry
Journal:  Biol Psychiatry       Date:  2014-06-23       Impact factor: 13.382

2.  Cocaine, but not amphetamine, short term treatment elevates the density of rat brain vesicular monoamine transporter 2.

Authors:  K Schwartz; R Nachman; M Yossifoff; R Sapir; A Weizman; M Rehavi
Journal:  J Neural Transm (Vienna)       Date:  2006-08-08       Impact factor: 3.575

3.  Imaging Cortical Dopamine Transmission in Cocaine Dependence: A [11C]FLB 457-Amphetamine Positron Emission Tomography Study.

Authors:  Rajesh Narendran; Neale Scott Mason; Michael L Himes; W Gordon Frankle
Journal:  Biol Psychiatry       Date:  2020-04-12       Impact factor: 13.382

4.  In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers.

Authors:  Rajesh Narendran; Brian J Lopresti; Diana Martinez; Neale Scott Mason; Michael Himes; Maureen A May; Dennis C Daley; Julie C Price; Chester A Mathis; W Gordon Frankle
Journal:  Am J Psychiatry       Date:  2011-10-31       Impact factor: 18.112

5.  Decreased expression of the transcription factor NURR1 in dopamine neurons of cocaine abusers.

Authors:  Michael J Bannon; Barb Pruetz; Amy B Manning-Bog; Christopher J Whitty; Sharon K Michelhaugh; Paola Sacchetti; James G Granneman; Deborah C Mash; Carl J Schmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

6.  Common human 5' dopamine transporter (SLC6A3) haplotypes yield varying expression levels in vivo.

Authors:  Tomas Drgon; Zhicheng Lin; Gene-Jack Wang; Joanna Fowler; Johnfn Pablo; Deborah C Mash; Nora Volkow; George R Uhl
Journal:  Cell Mol Neurobiol       Date:  2006-05-20       Impact factor: 5.046

Review 7.  Medication discovery for addiction: translating the dopamine D3 receptor hypothesis.

Authors:  Amy Hauck Newman; Brandi L Blaylock; Michael A Nader; Jack Bergman; David R Sibley; Phil Skolnick
Journal:  Biochem Pharmacol       Date:  2012-07-03       Impact factor: 5.858

Review 8.  2C or not 2C: phenethylamine designer drug review.

Authors:  Be Vang Dean; Samuel J Stellpflug; Aaron M Burnett; Kristin M Engebretsen
Journal:  J Med Toxicol       Date:  2013-06

9.  PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity.

Authors:  T S Guillot; J R Richardson; M Z Wang; Y J Li; T N Taylor; B J Ciliax; O Zachrisson; A Mercer; G W Miller
Journal:  Neuropeptides       Date:  2008-06-03       Impact factor: 3.286

10.  Excited delirium.

Authors:  Asia Takeuchi; Terence L Ahern; Sean O Henderson
Journal:  West J Emerg Med       Date:  2011-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.